Daniel Martínez Canca is an innovative researcher specialising in the intersection of artificial intelligence and oncology. As a member of iCCS iOncoCare and a recognised Harvard Medical School winner, he commands leading-edge expertise in developing AI-driven solutions to improve triple negative cancer diagnosis, treatment decision-making, and patient outcomes. His academic credentials — including an MSc and BSc with honours (Biomedicine), postgraduate training in Medical Genetics and candidacy for a PhD — are complemented by his status as a Fellow of the Higher Education Academy, underscoring his commitment to teaching excellence and mentorship.

Over his career, Daniel has consistently demonstrated thought leadership and strategic impact. He has contributed to internationally visible research aimed at harnessing AI methods — such as machine learning and predictive modelling — to address key challenges in oncology, including early detection, risk stratification, and personalised therapy planning.

His work bridges computational science, clinical insight, and ethical innovation, integrating data integrity, model transparency, and patient-centred values. Daniel’s collaborations span research institutions, clinical oncology groups, and technology partners, reflecting his ability to lead multidisciplinary teams and translate complex methods into meaningful clinical tools.

Mr Martínez Canca is guided by a strong sense of integrity and service. He places great importance on rigorous validation, fairness in AI, and ensuring that technological advances benefit underserved populations as well as well-resourced ones. His contributions have earned him recognition in prestigious forums and awards, and he serves as a role model for emerging researchers in health technology.

Mr Daniel Martínez Canca is proud to support the NouZetwals Health and Social Care Excellence Awards, and looks forward to celebrating those driving innovation, compassion, and excellence across health and social care.